Metraipolis › archive › dc_189d22b9167a
Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42114019
- DOI
- 10.2196/81323
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T12:28:44.997Z
- SHA-256 of the archived text
65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b- Stable URL of this page
https://metraipolis.com/documento/dc_189d22b9167a
How to cite
Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019 — Europe PMC (en), https://europepmc.org/article/MED/42114019 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_189d22b9167a (Metraipolis archive dc_189d22b9167a, sha256 65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b)
BibTeX
@misc{dc189d22b9167a,
title = {Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a,… — Europe PMC PMID:42114019},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42114019},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_189d22b9167a; sha256 65029fe99d7357fec8f78eeb1208d6222eaa91690e85f867d7cce360485b679b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42114019. Agents can read the archived copy with the MCP tool read_document.